Showing results (21-30 of 83) with videos related to
Sort By:
Pageof 9
Case Reports in Oncological Medicine|February 13, 2013
HHV8-Negative Primary Effusion Lymphoma of B-Cell Lineage: Two Cases and a Comprehensive Review of the LiteratureNeeraj Saini, Ephraim P Hochberg, Erica A Linden, et al.European Journal of Haematology|October 14, 2011
The Medical Research Council Myeloma IX trial: the impact on treatment paradigmsPaul G Richardson, Jacob P Laubach, Robert L Schlossman, et al.Journal of the National Comprehensive Cancer Network : JNCCN|October 7, 2011
Management of relapsed and relapsed/refractory multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.Journal of the National Comprehensive Cancer Network : JNCCN|November 3, 2009
Novel therapies in the treatment of multiple myelomaJacob P Laubach, Constantine S Mitsiades, Anuj Mahindra, et al.Molecular Cancer Therapeutics|August 31, 2014
Delineating the mTOR kinase pathway using a dual TORC1/2 inhibitor, AZD8055, in multiple myelomaDiana Cirstea, Loredana Santo, Teru Hideshima, et al.Clinicoeconomics and Outcomes Research : CEOR|September 18, 2023
Using a Modified Delphi Panel to Estimate Health Service Utilization for Patients with Advanced and Non-Advanced Systemic Light Chain AmyloidosisMorie Gertz, Rafat Abonour, Sarah N Gibbs, et al.Case Reports in Medicine|June 14, 2012
Hyperuricemic renal failure in nonhematologic solid tumors: a case report and review of the literatureNeeraj Saini, Kyeong Pyo Lee, Smita Jha, et al.Blood|March 3, 2016
Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myelomaRachid C Baz, Thomas G Martin, Hui-Yi Lin, et al.Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation|June 8, 2019
Autologous Stem Cell Transplantation for Multiple Myeloma: Growth Factor MattersJason Chen, Jonathan Pan, Tingting Zhan, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 25, 2011
Antimyeloma activity of a multitargeted kinase inhibitor, AT9283, via potent Aurora kinase and STAT3 inhibition either alone or in combination with lenalidomideLoredana Santo, Teru Hideshima, Diana Cirstea, et al.Pageof 9